Conference Roundup
Hematology
Von Willebrand Disease Phase III Clinical Trial Announced
Posted on
A clinical trial aimed at determining if intravenous recombinant von Willebrand factor (rVWF) is more effective than the current non-hormonal standard oral tranexamic acid in reducing menorrhagia in women with von Willebrand disease was announced at the 2019 American Society of Hematology annual meeting.
To watch the video of study author Margaret Ragni, MD, of UPMC Hillman Cancer Center discussing the study results, click here.
-Advertisement-
Related Articles
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 MedJournal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved